What is the likelihood that Smoldering Multiple Myeloma (SMM) with high-risk light chain lambda progresses to active Multiple Myeloma (MM)?
Light chain myeloma accounts for about 20% of myeloma cases. In this type, abnormal plasma cells produce only the light chain part of immunoglobulins (also known as Bence Jones Show Full Answer
What is the likelihood that Smoldering Multiple Myeloma (SMM) with high-risk light chain lambda progresses to active Multiple Myeloma (MM)?
Light chain myeloma accounts for about 20% of myeloma cases. In this type, abnormal plasma cells produce only the light chain part of immunoglobulins (also known as Bence Jones proteins). Light chain myeloma patients have a higher risk of developing kidney complications compared to other types. Key diagnostic indicators that doctors monitor include:
• Blood tests for M protein levels to track disease aggressiveness
• Serum-free light chain tests to measure excess light chains
• Urine tests to check for light chains
• Bone marrow biopsy to assess cancer cell presence
• Imaging tests to monitor bone or organ damage
Regular monitoring of these factors helps determine disease progression and guides treatment timing decisions.
September 14, 2025
Join
Your Privacy Choices
